Olpasiran clinical trials
Also written AMG 890.
How each study uses olpasiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the olpasiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses olpasiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular EventsRecruitingPhase 3AmgenNCT07136012Written as Olpasiran
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialRecruitingPhase 3AmgenNCT07293260On coronary plaque by CT angiographyWritten as Olpasiran
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic ImpairmentCompletedPhase 1AmgenNCT05481411In hepatic impairmentWritten as Olpasiran
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialActive, not recruitingPhase 3AmgenNCT05581303On cardiovascular outcomes (OCEAN(a)-Outcomes)Written as Olpasiran
- A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy ParticipantsCompletedPhase 1AmgenNCT06411860On the QT interval in healthy participantsWritten as Olpasiran
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal ImpairmentCompletedPhase 1AmgenNCT05489614In renal impairmentWritten as Olpasiran
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding StudyCompletedPhase 2AmgenNCT04270760Dose finding (OCEAN(a)-DOSE)Written as Olpasiran
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)CompletedPhase 1AmgenNCT03626662First in human, in high Lp(a)Written as AMG 890
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)CompletedPhase 1AmgenNCT04987320In Chinese participants with high Lp(a)Written as Olpasiran
Codes
What other systems call olpasiran · ClinicalTrials.gg INT001919
- MeSH (NLM) C000723009olpasiranOne source ClinicalTrials.gov
- UNII (FDA) 8M4GC1EOB4OLPASIRANOne source FDA
- NCI Thesaurus C175176OlpasiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723009 | olpasiran | One source ClinicalTrials.gov |
| UNII (FDA) | 8M4GC1EOB4 | OLPASIRAN | One source FDA |
| NCI Thesaurus | C175176 | Olpasiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.